CBER chief Prasad suggests Covid vaccine harms may outweigh benefits in 'low-risk populations'

Max Bayer

Pharma Reporter

CBER Director Vinay Prasad says the benefits of Covid-19 vaccination have depreciated and may no longer outweigh the risks in adults who aren’t prone to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

CBER chief Prasad suggests Covid vaccine harms may outweigh benefits in 'low-risk populations'

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Pfizer ends Phase 2 trial for final Trillium CD47 drug

Apple Tree Partners' biotechs 'face imminent collapse' as firm battles Russian investor in court

OpenAI-backed startup releases new AI models, claiming top performance in making antibodies

AbbVie bags Capstan’s in vivo CAR-T work with $2.1B buyout deal

Supreme Court passes on Oklahoma’s drug middlemen spat

Sage plans to lay off almost every employee after inking Supernus deal

CBER chief Prasad sug­gests Covid vac­cine harms may out­weigh ben­e­fits in 'low-risk pop­u­la­tion­s'

Max Bayer

Pharma Reporter

Sign up to read this article for free.

more like this

Pfiz­er ends Phase 2 tri­al for fi­nal Tril­li­um CD47 drug

Ap­ple Tree Part­ner­s' biotechs 'face im­mi­nent col­lapse' as firm bat­tles Russ­ian in­vestor in court

Ope­nAI-backed start­up re­leas­es new AI mod­els, claim­ing top per­for­mance in mak­ing an­ti­bod­ies

Ab­b­Vie bags Cap­stan’s in vi­vo CAR-T work with $2.1B buy­out deal

Supreme Court pass­es on Ok­la­homa’s drug mid­dle­men spat

Sage plans to lay off al­most every em­ploy­ee af­ter ink­ing Su­per­nus deal

CBER chief Prasad suggests Covid vaccine harms may outweigh benefits in 'low-risk populations'

Pfizer ends Phase 2 trial for final Trillium CD47 drug

Apple Tree Partners' biotechs 'face imminent collapse' as firm battles Russian investor in court

OpenAI-backed startup releases new AI models, claiming top performance in making antibodies

AbbVie bags Capstan’s in vivo CAR-T work with $2.1B buyout deal

Supreme Court passes on Oklahoma’s drug middlemen spat

Sage plans to lay off almost every employee after inking Supernus deal